Quantification of pulmonary inflammation by positron emission tomography in chronic obstructive pulmonary disease: A new horizon in the era of biomarkers?

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 11, 2012, Pages 1071-1073

  Jones, Hazel A ^a   Soler, Nestor ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EDITORIAL; EMPHYSEMA; HUMAN; NEUTROPHIL; PATHOGENESIS; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

BRONCHITIS; FEMALE; HUMANS; MALE; NEUTROPHIL ACTIVATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84870396829     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201208-1377ED     Document Type: Editorial

References (17)

1. Agustí A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;184:507-513.
2. Barnes PJ, Chowdhury B, Kharitonow SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in chronic pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14.
3. Turino GM. COPD and biomarkers: the search goes on. Thorax 2008;63: 1032-1034.
4. Jones HA. Inflammation imaging. Proc Am Thorac Soc 2005;2:545-548.
5. 18F-Fluordeoxyglucose positron emission tomographic imaging of pulmonary function, pathology, and drug delivery. Proc Am Thorac Soc 2009;6:477-485.
6. 13N PET as a vascular biomarker in chronic obstructive pulmonary disease. J Nucl Med 2010;51:57-65.
7. Bellani G, Messa C, Guerra L, Spagnolli E, Foti G, Patroniti N, Fumagalli R, Musch G, Fazio FMD, Pesenti A. Lungs of patients with acute respiratory distress syndrome show diffuse inflammation in normally aerated regions: a [18F]-fluoro-2-deoxy-D-glucose PET/CT study. Crit Care Med 2009;37:2216-2222.
8. Dolovich MB, Schuster D. Positron emission tomography and computed tomography versus positron emission tomography-computed tomography: tools for imaging the lung. Proc Am Thorac Soc 2007;4: 328-333.
9. Hany T, Steinert H, Goerres G, Buck A, von Shulthless G. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-581.
10. 18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma. J Nucl Med 2011;52:1713-1720.
11. Subramanian DR, Jenkins L, Edgar R, Quraishi N, Stockley RA, Parr DG. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J Respir Crit Care Med 2012;186:1125-1132.
12. Chen DL, Ferkol TW, Mintum MA, Pittman JF, Rosenbluth DR, Schuster DF. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med 2006;173:1363-1369.
13. Jones HA, Marino PS, Shakur BS, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003;21:567-573.
14. 18F-FDG uptake to assess eosinophilic inflammation in asthma: would SUV at late imaging be relevant? J Nucl Med 2012;53:1328-1329.
15. Jones HA, Clark RJ, Rhodes CG, Schofield JB, Krausz T, Haslett C. In vivo measurement of neutrophil activity in experimental lung in- flammation. Am J Respir Crit Care Med 1994;149:1635-1639.
16. Jones HA, Marino PS, Branley HM, Boobis AR, Shiner RJ, Vennart W, Phillips P, Ward J, Smart T, Ind P. Reproducibility of 18FDG-PET scanning in patients with COPD. Am J Respir Crit Care Med 2004;169:A880.
17. Jones HA, Choudhary M, Harris DHF. In vivo measurement of circulating leucocyte activation in patients following cardiopulmonary bypass. Nucl Med Biol 2004;31:965-969.